Seeking Alpha

Lannett takes issue with multi-state civil complaint over generic drug price fixing

|About: Lannett Company, Inc. (LCI)|By:, SA News Editor

In a statement, Lannett Company (NYSEMKT:LCI) says it has reviewed the civil complaint from the state attorneys general related to alleged price fixing by generic drug makers. Its involvement is limited to one product that it sells and it believes the charges are without merit. It intends to vigorously defend itself in the lawsuit.

Previously: Mylan leads generic drug maker selloff on expanded state probe into generic drug pricing; shares down 8% (Oct. 31)

Try Seeking Alpha PREMIUM for unlimited analysis on LCI